Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Swedish BioFINDER 2 Study

Next Previous
Trial Profile

The Swedish BioFINDER 2 Study

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Flutemetamol-F-18 (Primary) ; RO 6958948 (Primary)
  • Indications Alzheimer's disease; Cognition disorders; Neurodegenerative disorders
  • Focus Biomarker; Diagnostic use
  • Acronyms BioFINDER2

Most Recent Events

  • 06 Apr 2026 Planned primary completion date changed from 31 Dec 2028 to 1 Dec 2036.
  • 04 Dec 2023 Results (n=912) assessing plasma biomarkers for identifying Ab positivity and stage of tau accumulation published in the JAMA Neurology
  • 20 Jul 2023 Results using BioFINDER-2 data investigating whether CU individuals who are Ab-negative and tau-PET positive in the medial temporal lobe show cognitive decline and increases in CSF phosphorylated tau (P-tau) or tau PET over time, presented at the Alzheimer's Association International Conference 2023

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top